ERBB2 and breast cancer: The findings related to compounds 2, 20, and 28–31 are particularly noteworthy since triple-negative breast cancer lacks estrogen and progesterone receptors and has insufficient HER2 protein, making it ineligible for hormone therapy or HER2-targeted medications, thus limiting treatment options compared to other types of invasive medications for breast cancer.